NuVasive XLIF remains strong, says ThinkEquity

theflyonthewall.com

After conducting checks with doctors, ThinkEquity believes that minimally invasive lateral fusion procedures continue to grow despite a challenging environment, while NuVasive's XLIF remains many surgeons' favorite choice for lateral fusion. The firm maintains a $30 target and Buy rating.

Rates

View Comments (0)